Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Sarcoma 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Melanoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

vocimagene amiretrorepvec 1enfortumab vedotin 1catumaxomab 1apatorsen 1Ty21a typhoid vaccine 1Therapeutics 1Photochemotherapy 1Paclitaxel 1Mitomycin 1Imiquimod 1Gemcitabine 1Flucytosine 1Ethacrynic Acid 1Bevacizumab 1BCG Vaccine 1Antibodies 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Non-Muscle Invasive Bladder Neoplasms × BCG Vaccine × Clear all
NCT01498172 2015-02-04

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

University of Lausanne Hospitals

Phase 1 Completed
23 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡